Peptides: The Science, Uses & Safety | Dr. Abud Bakri

KEYPOINTS

• 01

  BPC-157 comes from a protein in gastric juice

  Bakri, an internal medicine physician, explains that in 1991 a group in Croatia isolated a large protein, BPC, from gastric juice. BPC-157 is a 15-amino-acid fragment of it, and the body doesn't make that fragment on its own, despite what is often claimed online. The researchers were following two leads: Pavlov had sold dogs' gastric juice as a remedy for stomach complaints, and Hans Selye showed that stress damages the stomach lining, so they suspected the gut produced something protective.

• 02

  BPC-157 seems to boost healing rather than suppress inflammation

  In animal models it increases VEGF signaling and new blood vessel growth, helps cells move into wounds, adjusts nitric oxide production and, in one tendon model, increased growth hormone receptors on the tendon. Mice given corticosteroids, which normally slow wound healing, healed as well or better when BPC was added. Bakri finds its gut and brain effects more interesting than the muscle-and-joint hype. In mice it reduced intoxication from alcohol and blocked withdrawal symptoms.

• 03

  The human evidence for BPC-157 is thin

  Almost all the animal research comes from the single Croatian group. In humans there were only small phase 1 and phase 2 trials of BPC enemas in the early 2000s: no adverse events in phase 1 and a positive signal for ulcerative colitis in about 40 patients in phase 2. Nobody knows the right human dose. Most people inject 100–200 mcg a day based on what research websites sell, and Bakri suspects the effective dose is far higher.

• 04

  The cancer question is still open

  There is no sign of cancer in the animal research, and Bakri says there's no mechanism by which BPC would cause cancer the way smoking does. Because it promotes blood vessel growth, though, it could in theory feed an existing tumor. One melanoma cell study showed it reduced VEGF. Online users report worsening hematomas, and a physician friend of Huberman's noticed his facial spider veins getting worse.

• 05

  In the US, the legal status is unsettled

  BPC-157 was never FDA-approved. In late 2024 it and about 20 other peptides were moved to the FDA's 'category 2' list, which blocks compounding. That pushed people toward 'research use only' gray-market vials, which can vary from batch to batch. As of this conversation, BPC-157 had been taken off category 2 but not yet added to category 1, the list that would let doctors prescribe it through compounding pharmacies. Black-market powder from China costs about $5 a vial to make.

• 06

  Khavinson's 'bioregulator' peptides are meant to keep working after you stop

  Soviet researcher Vladimir Khavinson isolated short peptides from organs. Examples are pinealon (the tripeptide EDR, with no known receptor), epitalon from the pineal gland, and several thymus peptides. The idea is that short courses shift gene activity and the benefits continue afterward. Bakri repeatedly attaches a caveat: the evidence is largely Russian literature.

• 07

  Thymosin alpha-1 stimulates T-cells

  The thymus grows from birth until puberty and then shrinks. Thymosin alpha-1, a peptide of about 21 amino acids from Goldstein's lab, helps T-cells develop and multiply. It's approved in other countries as an add-on therapy for hepatitis B and C and some cancers, but results for sepsis and infection have been unimpressive. Bakri, speaking from personal use and not as a recommendation, injects 2.5 mg twice a week while traveling and on hospital rotations.

• 08

  Restoring growth hormone with age is a double-edged choice

  IGF-1 falls dramatically between 18 and 50 (sometimes called somatopause). Growth hormone benefits skin, sleep, recovery and the thymus, and no one thinks it causes cancer. However, it could speed up an existing cancer, it isn't good for heart and metabolic health, and growth hormone–deficient models live longer. Huberman's example is that large, high-IGF-1 dog breeds live shorter lives.

• 09

  Some GLP-1 side effects may come from misuse

  Bakri sees GLP-1 drugs as 'training wheels' for weight loss. He suspects that reported cognitive problems may stem from doses that are too high, too few electrolytes or nutrients, low blood sugar, or eating less socially, rather than from the drug acting on the brain. Women with obesity sometimes conceive unexpectedly on these drugs because weight loss changes leptin, a key fertility signal.